Anti-GPIIIa antibody and CD4 count identify an autoimmune-enriched phenotype of HIV-associated thrombocytopenia: development and internal validation of a clinical nomogram - Scorecard - MDSpire
Advertisement
Anti-GPIIIa antibody and CD4 count identify an autoimmune-enriched phenotype of HIV-associated thrombocytopenia: development and internal validation of a clinical nomogram
Clinical Scorecard: Identification of an Autoimmune-Enriched Phenotype in HIV-Related Thrombocytopenia Using Anti-GPIIIa Antibody and CD4 Count: Creation and Internal Validation of a Clinical Nomogram
At a Glance
Category
Detail
Condition
HIV-related thrombocytopenia
Key Mechanisms
Autoimmune platelet destruction and advanced immunodeficiency
Target Population
HIV-infected individuals with thrombocytopenia
Care Setting
Clinical prediction model development and validation
Key Highlights
Anti-GPIIIa antibody positivity is a dominant predictor of thrombocytopenia.
The final model achieved an AUC of 0.862 with high specificity and positive predictive value.
Distinct risk trajectories were observed based on CD4+ T-cell counts and anti-GPIIIa antibody status.
Guideline-Based Recommendations
Diagnosis
Utilize anti-GPIIIa antibody testing alongside CD4+ counts for risk stratification.
Management
Further immunological evaluation for patients identified with autoimmune-enriched thrombocytopenia.
Monitoring & Follow-up
Regular assessment of CD4+ T-cell counts and platelet counts in HIV-infected patients.
Risks
Severe thrombocytopenia poses risks of hemorrhage and complicates treatment.
Patient & Prescribing Data
HIV-infected individuals with thrombocytopenia
Treatment response was not prospectively evaluated; further studies needed.
Clinical Best Practices
Integrate immunological markers with routine clinical parameters for thrombocytopenia risk assessment.
Consider the presence of autoantibodies in the context of overall clinical picture.
